Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pretty quiet Monday morning. I would expect some type of news tomorrow, be it a PR on recent Meeting on the Mesa (low level PR), a PR commenting on indolamine 2,3 study done elsewhere cited by N4T, a product line update or the PR we are really waiting for, FDA approval of HemaXellerate.
Those are RGBP preferred shares, Series A I believe. Not yet tradeable.
Yeah, I remember a Friday PR after hours that had very little effect come Monday morning. Generally speaking Fridays are a lousy day to release a PR, especially after hours.
Better Monday morning right before open, but I suspect the next PR will be Tuesday morning.
T-Rex, if you go to the bottom of the page you linked to, it gives a very good overview of the 3 day meeting, which actually has 3 different venues for 3 different purposes, Partnering, Scientific Symposium and Public Forum. C. Ichim participated in the Scientific Symposium which gives direct exposure to her research while indirect exposure to the company. Maybe next year RGBP will be asked to be a company presenter, but we hope they get significant partners before then.
One other note, the Scientific Symposium was held at the Salk Institute where C. Ichim has done research in the past. So that is another good sign and connection for the company to get exposure.
Well, T-Rex, RGBP released a PR stating that C. Ichim had been asked by the organizers to present at the Meeting on the Mesa. (She had submitted an abstract and we were told she was then asked to present).
Now, there were different levels of "presenters" and "presentations". The main "presentations" listed each day on the Meeting website were company presentations since the meeting's goal was to connect companies with collaborators or $$$ for their projects.
RGBP did not have a slot for a company presentation (which were being made available after the meeting. Instead, C. Ichim was listed as a presenter during I believe the last day's scientific discussion symposium which provided opportunity for scientific updates and presentations I imagine in a more limited fashion than the more extensive company presentations where companies talked about any and every aspect of their company and were not limited to a specific scientific update.
Most convertible share loans were done between March 3 and March 19th, 2015, so I believe RGBP is holding back on news until Oct 19th in order that holders of convertible note shares will have another 1/6th of their shares available for selling (as a kind gesture to the "angel" investors). The first 1/6th or about 5 million RGBP shares released last month and the second 1/6th or another 5 million release this month by Oct 19th.
Ergo, look for PR next Tuesday as a good chance for something significant. If nothing else, we should get PR update on Ichim presentation at Meeting on the Mesa.
GM, but is it a good news or sign that he has been all over the place, but for very short times. I don't like the pattern of holding many jobs after academia, all for only 1-2 years at a time. If he was successful in bringing 50 companies to the NASDAQ and that's all he did during his tenure with RGBP, probably is worth it in long run, but his resume of not holding down positions for very long and his release/firing/quitting Sidra does not build confidence for me.
Almost as if Koos is afraid of putting someone truly capable in charge for fear of losing his own control. Don't know. All speculation, but Landers brings some red flags along with Resume. Time will tell.
Here is cached page of Lander's profile at Sidra when he was part of Sidra. This page is no longer part of Sidra website, but Sidra just got 3 grants from Qatar's National Health research for 3 new research projects. Each grant is worth $800,000. There is money is Qatar.
Lander's previous profile listing (he as a securities trader for a while):
http://webcache.googleusercontent.com/search?q=cache:PtEzbXeB1S0J:www.sidra.org/harry-lander/+&cd=4&hl=en&ct=clnk&gl=us
Most promising line of PR is:
I've been in since the first news of the first IND back in 2013 in BMSN and still waiting. 2015 has shown the signs (via PRs at least) of being the year of a new beginning for BMSN/RGBP with RGBP now clearly at the forefront of all development.
I have not sold, but only added over the course of the last couple months, but I certainly expected more concrete news of the HemaX IND safety data submittal by this date. With all the PRs RGBP has released on lesser news and issues, one would think we would have a clear PR on when the safety data was or will be submitted for final FDA review. That would be normal transparency for a company. Koos' release in the past of 'positive' PRs only to turn into silence for weeks and then an update that the positive news wasn't completely positive because of this or that is a past that is real and that is why getting the full HemaXellerate picture is so important and FDA approval for this to take off.
The fact that even on a day of C. Ichim's presentation at the Meeting on the Mesa ends in a low volume down day is nothing that I can get excited about and goes against the grain of investors being interested in all the progress YTD. Maybe they are. Maybe there is a blockbuster deal forming, but until I get consistent transparency from the company (Koos), his past casts a dark shadow.
dMort, less than $5,000 worth of stock bought today and more than the entire day's buy still sitting at .17.
Only a PR stating full FDA approval for phase 1 clinical trials will get us moving in the right direction. In spite of all the positive news PRs, this has drifted down to trading sideways as we approach the time we are expecting FDA approval which to me is not an encouraging sign.
I truly thought we would at least be in the mid .20s at this point if FDA approval was secure and Orphan Drug Status a short step away. From RGBP's PR, that was certainly the impression they wanted to leave us with. So why no follow up news as we approach the 4th week from the CRL safety data due date of Sep 16th is anyone's guess.
We must remember than another 5 million shares from the "angel investors" or about 200,000/day are being released for trade each month beginning in Sept and continuing through Feb 2016.
The fact that most of the RGBP board of directors and T. Ichim are members of multiple start ups may or may not be good news for us.
My hope that 2015 is the year of the turn around for RGBP depends on getting the HemaX approval PR and some concrete news on dCellVax modified IND submittal before the end of the year I think, or the 30 million shares coming into trading will most likely keep us bobbing up and down in the backwaters. Those 30 million shares were sold at under .03, so even at .15-.17 cents, the angel investors make hundreds of thousands.
With every tick down and day that goes without news on HemaX and FDA, my stomach is sinking. The action taking place here after we got 3 PRs in rapid succession and no word on FDA submittal or approval does not bode well with my gut feelings.
The insiders already know and they tend to leak news to others and good news drives prices up while bad news degenerates the price even before the official news is released. Having the price fail after "positive" CRL safety test results makes no sense and I fear we are in for another "delay" that Koos and the company is working to resolve in a "timely" manner. Releasing soft PRs in rapid succession as lead up to big PR on HemaX submittal or approval made sense. Those PRs in place of any news on HemaX test results submittal and/or FDA response is bad sign.
Thanks for both for posts.
Maybe I was wrong in assuming that her poster abstract presentation had been "upgraded" to a more general presentation, but good to confirm that she and RGBP are listed. Also note from PR that her presentation isn't until Oct 9th during the scientific symposium and not part of the company presentation portion of the conference. So while RGBP has not earned yet to be part of the official company partnering portion of the conference, her scientific presentation should get noticed and if we get FDA news within next 2 weeks, it should provide further partnering interest.
At least she is putting RGBP in the ballpark of this high profile, money rich crowd.
Cannot find Regen Biopharma nor Christine Ichim's name on the website or list of presenters at the Stemcell meeting on the Mesa - very odd and not encouraging. RegenXBio is listed, but they are a different company.
Maybe only companies presenting as a company are listed and since C. Ichim's presentation is an upgrade to a submitted abstract, those talks are not listed. I don't know, but the agenda is packed and focused on partnering with companies giving presentations and I cannot find RGBP as a presenting company.
Next Wednesday is Christine Ichim presentation. Also expected within next 2 weeks is PR on FDA submission/approval of HemaXellerate IND for clinical trials (only 10 patient enrollment, so could get underway fairly quickly) followed by Orphan Drug Status.
All of this based on info in previous PRs
Good point about UCSD. Regen, from the CIRM article is not listed as one of the 5 clinical trials currently funded by CIRM, but the fact that Dr. Kesari heads up a dept at UCSD and is working on dCellVax for glioma as well as modifying dCellVax IND for clinical trials, leaves the door open for possible CIRM funding of future RGBP clinical trials as who you know is very important.
When someone continually posts against reasons and facts, we have the great tool on this board of the ignore function. Just click on the offenders name in a post and when it brings you to his/her profile page, choose the icon of "Ignore" and their posts won't show up for you.
Saves having to read a lot of nonsense, saves time and helps bring the focus back to actual reflection of the company and what is happening.
Don't lose sight of this significant partnership announced back in June 2015 (now 4 months into the process of helping/modifying the IND for dCellVax). Can certainly hope that progress is such that after FDA approval news for HemaX, RGBP can issue a PR on the refiling of IND with new data for dCellVax and then based on that, make some good and more beneficial investor package to raise the funds or take out a line of credit to fund the trials.
Ok RGBP bulls, while RGBP received the audited HemaX report only recently, we suspect they knew the general outcome (positive/negative) safety results of the test before that.
To maximize the impact of FDA approval news, one would think they have a plan as to what other news to release and when as to the timing of the FDA approval news.
It is my belief that that FDA news is coming shortly and the recent release of several other PRs is a planned lead up to that news.
Just look at the PR headlines of the month and the recent rapid release of 4 PRs over the past week:
Regen BioPharma, Inc. Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent ResearchersPR Newswire(Tue 8:30AM EDT)
Regen BioPharma, Inc. Director of Molecular Therapeutics to Speak at Stem Cell Conference Regarding Leukemia Research Being Conducted by the CompanyPR Newswire(Mon, Sep 28)
Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXelleratePR Newswire(Fri, Sep 25)
Regen Biopharma Inc. Initiates Small Molecule Hit Validation Study on Cancer Stem Cell Target GenePR Newswire(Wed, Sep 23)
Regen BioPharma, Inc. Files Utility Patent Application on Immune Based Therapy for CancerPR Newswire(Wed, Sep 16)
October should be even better with new speaker's engagement on NR2F6 just a week away, the fine tuning and narrowing of 170 compound "hits" for treating cancer down to the top candidates (after a narrowing of over 30,000 compounds down to 170 with their proprietary, patented process, FDA approval for HemaX and possibly Orphan Drug Status within October as well. And these are only the known elements of development we should expect updates on in October. Who knows what other positive surprises might be in store.
Since positive news on OTC stocks takes longer to get around and noticed, I suspect we might be in store for several days of heavier positive volume on the PRs already released.
Here's to the future and 2015 being the "turnaround" year for RGBP.
For those without LII, Nite is hiding 20,000 share bid at .20 with CDEL behind at .1901 with over 13,000, PUMA at .19 with 5K.
We have PUMA on ask at .21 showing 2500 (unchanged after 2600 shares purchased) and NITE showing 6,000 on ask at .22, then .24 next
Right now I'm glad I took a couple thousand out of cash and added shares when stock was trading a while back at .12 but didn't sell in low .20s. Was tempted, but with the PR that CRL studies on HemaX came out well, it is only a matter of a short time before RGBP should be able to get some legs of support underneath and begin a more significant climb.
Once HemaX is FDA approved and Orphan Drug Status news is released shortly thereafter (within a couple weeks to a month), then suddenly RGBP is finally a legitimate R&D company on paper with momentum and the continual whining of the past should be behind us even though ones history is always somewhat of a reference point.
But suddenly, when new people begin looking at RGBP, seeing FDA approval and orphan drug status for 1st pipeline product, now Kesari's being on board to advance DCellVax will be perceived as a huge plus and as I've been saying since early in the year, NR2F6 could outclass both HemaX and DCellVax in significance.
Instead of having to wait 6 months to a year hoping for good news, I can sit back knowing that a milestone has been passed and we are on much more solid ground for the future.
Yeah.
A 1 share trade has to mean some type of game is being played. Not normal trading, but as others have pointed out, the world of OTC is different.
Low trading volume is remarkable. Timing is important and about the only theory I can think of for low volume is that we are at end of Qtr and often people/companies take the more risky stocks out of their portfolio for Qtrly reports.
We've had huge volume days on lesser news than what we received the past week, so whatever is happening is a bit strange. I would look to see how trading goes come Oct 1st with the Oct 7th presentation. I would think we rise to mid .20s at least.
Sid, if you consider less than $5,000 in shares traded as "share dumping", then you have very small pockets indeed.
And therefore, what is your long term outlook for the company and the reason why you continue to post the same stream regardless of the actual progress and developments of the company?
Today's PR seems to indicate an upgrade of N4T's link last week that showed RGBP with a poster abstract for the Meeting on the Mesa stem cell conference. It appears, as happened at a previous conference this year, that the abstract was upgraded to a presentation. This is more good news and affirmation of the progress the scientists and therefore the company has made in 2015.
I too am a bit stunned to find out only 59K shares were traded after this news and less than 10% increase in PPS. I had anticipated much more activity on both levels.
I would add a couple points to others' comments as well:
1. It was a Friday morning PR and that is not optimal.
2. OTC news takes time unless it is a P&D (so good sign we are not in that circumstance and I too think Monday brings in much more investment money and this could/should open at .20 or above based on Friday PR).
3. While we know the history of HemaX filing and FDA approval of other components, others do not, so big money might not react until PR release of actual FDA approval is released
4. Orphan Drug status is guaranteed after FDA approval for clinical trials - which should also move the price
5. Koos/Cavens might be timing some of the PRs to coincide with the presentation at CIRM meeting in CA (Oct 7-9)
6. Getting FDA approval notification around the time of the CIRM stem cell annual mtg could really be beneficial to RGBP catching the eye of some CA venture capitalists.
More good things to come. While price movement on Friday is disappointing, the real positive is that positive test results which should give everyone here more confidence for the future of the company.
Thanks LaddyMan for posting excerpt of News4This's link. This is a CIRM organized event ($$$) and what I find very encouraging is a) note the presenters outside of RGBP cooperating in this presentation and b) this is an update telling us that the development of NR2F6 (which we haven't heard much about for a while) has been ongoing and progressing. They aren't going to release a PR with every scientific experiment, but these presentations act like updating PRs to the scientific community and are a very good sign that company is indeed moving forward. HemaX is only first in a line of several products to come. Yes, RGBP will need money to advance these to clinical trials, but having multiple clinical trials will also give much more credibility and exposure for the company and should hopefully impact PPS more than the added shares needed.
Been traveling and just now reading up on board exchange.
Great to have the official results and no, Sid, this is not old news. The news we had previously was after 14 days and the tests and monitoring was ongoing, so I believe the news about the report confirming the safety of HemaXellerate goes beyond the first 14 days of observations.
Earlier, you posted that the PR was "GREAT NEWS", "as you had predicted". Now you are saying it is a rehash of old news. Can't really have it both ways.
Definitely looks like we will have to expect news next Tuesday, but the longer we go without downside selling pressure, the better the chances are for good news it seems.
And every one, especially new people should keep in mind, the goals of the company were indirectly laid out in the point system for the Ichims to be able to fully invest their bonus shares according to the hiring agreement they signed. Within 18 months, it laid out the course for the filing of new patents, the development of new treatments, the signing of new scientists to the board, the acceptance of abstracts or giving of presentations at conferences etc.
They are fulfilling the 18 month plan laid out back in Jan/Feb 2015 and hopefully not only will HemaX test results be the first major turning point of validated progress for RGBP, but over the course of the upcoming months, we will see the rapid progression of the other development projects under the guidance of the likes of Dr. Kesari and others.
Ebola was never the focus of this company. Even in the Ebola PR they stated that development was not imminent and would not occur within the next year, so bringing up Ebola as an issue is not pertinent.
Let's analyze what the company is focused on: HemaXellerate I - testing by an outside reputable company CRL whose report is due soon. Let's judge success or failure by the facts of the results, not nonsense. We don't know the results - that is a fact.
dCellVax - continuing development with hiring of Dr. Kesari, a cancer expert working in one of the few NCRI certified clinics who is partnering with RGBP to not only revise the IND for dCellVax for greatly chance of successs, but is interested in applying the research to glioma.
NR2F6 -this could be the golden egg, research showing the possibility of maturing cancel stem cells into healthy cells through differentiation.
BORIS - T cell immuno therapy studies that are gaining ground elsewhere, while RGBP holds IP patents.
I seem to recall a PR that mentioned Dr. Kesari was contracted to help with dCellVax IND and possibly adjust or expand it as well as applying the research to address glioma.
Then we had news that Dr. Kesari was successful in performing tests showing efficacy theory. Today's PR sounds like a further piece of possibly a much more effective IND for dCellVax if not a possibly new IND.
Very Cool. The fact that CRL is already embedded in using this means the transfer of Data to FDA should be very swift and will make it easier for th e FDA to review and approve if the data is positive.
Thanks for posting.
Hey Jack, check the calendar - today is only the 15th. AAAaaarrrrgggghhhh.
We shall see. If we don't have positive news within next Tuesday, I will be highly disappointed. We need, the company needs this expensive CRL test data to be solid and positive.
If not, the price will fall far below .10 in my opinion. But if it is conclusively positive, we can leave the .20s and .30s and hopefully the .40s behind for good.
Got it. As others mentioned, but I didn't catch initially, this reference is most likely due to the IP that Regen had licensed from OHSU for exclusive rights only to find out later than the Univ. hadn't renewed the patent. I don't think this is new news. Here's a quote of 8K filed back in August 2013:
New4This, I clicked on link and did not see anything mentioning RGBP while stating you had to pay $250 to access the report.
So did you purchase the report and within the report it mentions the option with RGBP you talk about? Can you give us a little more info?
True, if they wait until they submit the report, analysis and answers to FDA before releasing a PR on the test results, we could be looking at a week from tomorrow or later. Let's hope we get the good news just on the test results tomorrow and the submission PR the following week and then the FDA approval PR in mid October.
Shuffled in anywhere would be a positive PR regarding dCellVax IND update...
Based on what do you say that when a public PR stated Sept 16th?
July 9, 2015 RGBP PR:
1 Trading Day left to Sept 16th Audited Rpt arrival expected at RGBP. If the safety testing news is negative, I believe per Trazbull's previous posts, any material news that is bad must be reported within 4 business days, so we should hear about it soon. On the other hand, if news is good as we expect, then we should either get a positive PR which I would expect or silence if they choose until they submit the data to the FDA.
I don't think they will wait until the FDA approves HemaX to issue a PR.